ECM Skin Boosters (hADM) — What They Are and How Far the Evidence Goes

Three-Line Summary

• The raw material of ECM skin boosters is human acellular dermal matrix (hADM), made from donated human skin with the cells removed. In sheet form, this dermal matrix was already being used to treat deep burns in the 1990s, and in powdered form it was used in the early 2000s as a filler to add volume to the lips, but placing it thinly in the dermis as a skin booster is a new use.
• In people, the research on its use as a skin booster is still small and short. Within the scope of our search, the published comparative clinical trials of this use came to one study, which followed 20 people for 20 weeks, and whether results last and whether there are rare side effects cannot yet be known.
• These products are regulated not as drugs or medical devices but as human tissue, so they do not go through an approval process product by product. Korea's Ministry of Food and Drug Safety (MFDS) takes the position that using human tissue for cosmetic purposes is not appropriate, and is carrying out research to redefine the management standards (as of October 2026).

What It Is Made From — Human Dermis with Only the Cells Removed

The dermis of the skin is made up of fibers such as collagen and elastin and the ground substance that fills the spaces between them. This structure is called the extracellular matrix (ECM). Human acellular dermal matrix (hADM) is a material made from donated human skin by removing the epidermis and the cellular components and leaving only this ECM structure. The cells are removed to reduce the immune reactions that another person's cells can provoke.

The material itself is not new. Acellular dermal matrix in sheet form was already being used to treat deep burns in the 1990s. In a multicenter study of 67 patients with deep burns (Wainwright et al., Journal of Burn Care & Rehabilitation, 1996), the rate at which the dermal matrix took (at 14 days) did not differ statistically from that of sites grafted with the patient's own skin alone, and where a thin graft of the patient's own skin was laid on top of it, the result over time was similar to that of sites given only a thicker graft of the patient's own skin. On biopsy, fibroblasts were seen moving in and new blood vessels growing, without rejection.

To make an ECM skin booster, this dermal matrix is frozen, dried and ground into a fine powder, which is mixed with a liquid such as saline at the time of treatment and injected into the dermis (MTN, 2026-04-29). In Korea, products such as Re2O and CellREDM belong to this category, and at the October 2026 audit it was pointed out that some 20 companies are distributing around 100 products (Medical Newspaper, 2026-10-13). Some products use donated skin tissue imported from abroad as their raw material (Business Plus, 2026-10-08).

The material may be the same, but grafting it onto a wound as a sheet and injecting it as a powder into the dermis of the face for cosmetic purposes differ in both method and purpose. That difference is at the center of the current regulatory debate (see 'Where Regulation Stands' below).

The types of skin booster as a whole, and how they work, are set out separately in our article comparing skin boosters and collagen stimulators.

How It Is Said to Work — Laboratory Results and Results in People Need to Be Read Separately

One manufacturer describes the concept not as adding a new substance but as refilling the dermal structure that was there to begin with (Dailypharm, 2026-04-30). The reasoning is that the dermal ECM that diminishes with age is replenished with the same kind of material.

There are laboratory results that support this explanation. In a study published in 2026 (Lee et al., International Journal of Molecular Sciences, 2026), fibroblasts moved in around hADM powder placed in rat skin and new collagen was formed, and in cultured fibroblasts, markers related to collagen and elastin increased. In an experiment in which it was injected into pieces of human skin, the powder spread evenly through the dermis.

Even so, results from 4 rats observed for 1 week, or the responses of cells in a culture dish, cannot be taken to appear in the human face to the same degree and over the same length of time. Laboratory results are 'reasons it might work'; how much the skin actually improves, and for how long, has to be confirmed separately in studies in people.

Studies in People — What Has Been Published So Far

A Comparative Trial as a Skin Booster — 20 People, 20 Weeks

In a study at Severance Hospital, 20 people aged 30 to 65 were recruited and the two sides of the face were compared over 20 weeks, with an hADM product (Re2O) mixed with hyaluronic acid injected on one side and a hyaluronic acid skin booster alone on the other (Lee et al., 2026). Which side received which was randomized, and the design was double-blind, so that it was not known which side was which. The side that received hADM did better on several measurements, such as skin density, volume, hydration, wrinkles and pore area. The point at which a difference appeared varied from measure to measure: volume differed at every assessment, pore area from week 12, and skin density at week 20. There were no serious adverse events, and mild redness and swelling were reported to have settled without treatment.

The limitations the authors themselves stated need to be read alongside these results.

• With 20 participants and a design that compares the two sides of one person's face, the results are hard to generalize widely.
• Because follow-up went only to 20 weeks, how long the effect lasts after that, and side effects that appear later, cannot be known.
• Because hyaluronic acid was mixed in with the hADM, the effect of the hADM on its own is hard to separate out.
• With so many measures, chance differences may be mixed in, and no statistical correction was made to account for this.

In addition, the product used in the study was supplied by the manufacturer, and the corresponding author disclosed having been involved in the product's development as an adviser. The trial was registered in September 2025, after the study period had ended. The product's manufacturer also cited the 20-person, 20-week trial as its evidence at a briefing in April 2026, and said it is gathering larger-scale data (MTN, 2026-04-29).

Studies as a Filler — A Different Use

Studies that injected acellular dermis in powdered form existed before this, but most used it as a filler to add volume. In a US study in which 44 people whose lips had thinned were divided between micronized human allograft dermis (Cymetra) and a bovine collagen filler, given several injections and followed for 1 year (Sclafani et al., Archives of Facial Plastic Surgery, 2002), the proportion of people in whom the red part of the lip increased by 20% or more was higher in the allograft dermis group (84.6% vs 38.9%), and there were no major complications. A multicenter study in China that used micronized acellular dermis made from pig skin as a filler for nasolabial folds (Zhang et al., Aesthetic Plastic Surgery, 2026) compared it with a collagen filler in 202 people and reported a similar correction effect up to 6 months, but pain after injection (40.7% vs 10.1%) and swelling (45.4% vs 13.5%) were more common. The discussion in the paper notes that some reactions lasted more than two months and that some cases needed treatment with medication.

These are results from use as a filler, and in one of them the material was made from pig skin rather than human skin, so they cannot be carried over as they stand to ECM skin boosters, which are placed thinly in the dermis.

To Sum Up

Within the scope of our search, there was one published comparative clinical trial of human-derived allograft dermis used as a skin booster: the 20-person study above. How many months the effect lasts, and how many sessions at what interval are advisable, are still hard to answer from research. There is 1 small study in which it did better than a hyaluronic acid skin booster (see the limitations above), but we did not find any study comparing it with other skin boosters.

Safety — What Has Been Reported and the Concerns Raised

Most of the side effects reported in studies were redness, swelling and pain at the injection site, and they were usually mild and temporary. In a study that used material made from pig skin as a filler, however, pain and swelling were more common than in the comparison group, and the paper's discussion notes some cases that lasted more than two months. Because so few people have taken part, small studies like these make it hard to know whether rare side effects exist.

At the October 2026 audit, the following concerns were raised (Medical Newspaper, 2026-10-13; Dailypharm, 2026-10-14).

• Cases of adverse reactions — it was pointed out that cases of inflammation, nodules, redness, swelling and pigmentation have been posted online. This came with the caveat that these alone do not establish that the product was the cause.
• Residues from processing — citing recent papers, the possibility was raised that detergents (such as SDS) that may be used in removing the cells (decellularization), and DNA that was not fully removed, could remain in the product.
• Storage and shelf life — shelf lives differ from product to product, at 3, 5 or 7 years, and a question was raised as to whether powdered products can be kept at room temperature for years at a time. The Minister of Food and Drug Safety explained that powdered products come into little contact with moisture and so can remain stable for relatively longer than liquid or gel products.

In decellularization, how much of the ECM's structure and biological properties is preserved depends on the chemicals and methods chosen (Crapo et al., Biomaterials, 2011). One manufacturer says its product has been used more than 300,000 times with no serious adverse events reported, and that it assigns 1 lot number per donor so that, if a problem arises, the product can be traced and recalled (Dailypharm, 2026-04-30). These are figures given by the company, not data that have been independently confirmed. The MFDS has also said it is reviewing ways to strengthen the adverse event reporting system and broaden labeling requirements (Dailypharm, 2026-04-20).

Where Regulation Stands — As of October 2026

Not a Drug or Medical Device but 'Human Tissue'

Skin falls under human tissue as defined by Korea's Safety, Management, etc. of Human Tissue Act, and procuring, processing, storing or distributing human tissue requires a tissue bank license from the Minister of Food and Drug Safety. Among injectable skin boosters, products classified as medical devices must have their intended use and indications approved before they can be distributed to hospitals and clinics, but ECM skin boosters, which are classified as human tissue, are supplied without a product-by-product approval process (MTN, 2026-04-29). This manufacturer says that only the way they are regulated is different, which does not mean they go unregulated, and that it manages the whole process from donation through processing and distribution to use (Dailypharm, 2026-04-30).

The Positions of the MFDS and the Ministry of Health and Welfare

• At a National Assembly forum in April 2026, the MFDS stated that using human tissue for cosmetic purposes is not appropriate (Dailypharm, 2026-04-20). At the audit on October 13, the Minister of Food and Drug Safety replied that this position still stands (Medical Newspaper, 2026-10-13).
• At the same session, the Minister of Food and Drug Safety said that human tissue had never been approved for cosmetic purposes, but that current law contains no provisions governing the advertising of human tissue. The Minister also said that a policy study to redefine the criteria and the management system, including whether skin tissue processed into powder can be regarded as 'minimal manipulation' (processing to a degree that does not change the tissue's original structure and function) and whether it should continue to be managed as human tissue, would be completed within this year (Health Kyunghyang and Medical Newspaper, 2026-10-13; Dailypharm, 2026-10-14).
• At the audit on October 7, the Minister of Health and Welfare replied that the current Human Tissue Act alone has limits as a means of oversight, and the Ministry of Health and Welfare said it is reviewing with the MFDS a plan to manage cosmetic ECM products within the medical device framework (Business Plus, 2026-10-08).

One manufacturer argues that grinding it into powder is only physical processing to make it easier to inject, that the function of the collagen and elastin structure is preserved, and that it therefore qualifies as 'minimal manipulation'. The opposing view holds that the process of removing the fat and grinding the tissue into powder should be regarded as additional manipulation (MTN, 2026-04-29). Depending on how this is judged, the classification and the way these products are managed may change.

Reading Advertising Claims

At the audit, it was pointed out that phrases such as 'certified tissue bank', 'FDA-approved raw material' and 'approved by Korea's MFDS' can be misread as meaning that the individual product's safety and efficacy have been approved, even though that is not what they mean (Health Kyunghyang, 2026-10-13). The MFDS was reported to have sent tissue banks an official letter asking them to refrain from promotional and advertising expressions (MTN, 2026-10-13). If you come across wording like this, it is worth distinguishing whether the 'approval' concerns the product's effects and safety, or the tissue bank or the raw material.

If You Are Considering the Procedure — What to Check

• Expectations — the evidence in people currently stands at the level of a study that followed 20 people for 20 weeks. It is a good idea to decide on the understanding that how long the effect lasts is not yet known.
• A record of what you received — ask whether the product name and lot number will be kept in your medical record. That way they can be checked later if an adverse reaction develops or something like a recall happens.
• What 'approval' means — check whether approval or certification wording in an advertisement refers to the effects and safety of the product itself.
• How things go after the procedure — redness and swelling usually settle on their own. If you can feel a firm lump, or if swelling, pain or redness does not settle and keeps getting worse, let the clinic that treated you know right away.
• Other options — for the same concern there are other approaches, such as hyaluronic acid or PN (polynucleotide) skin boosters, collagen stimulators, and lasers or radiofrequency. Which one suits you is better decided by examining your skin in person.

In Summary

• An ECM skin booster is a procedure in which dermal matrix made from donated human skin with the cells removed is ground into a powder and placed in the dermis. The material has long been used in burn treatment, but its use as a cosmetic skin booster is new.
• Laboratory studies have results that could serve as supporting evidence, but comparative clinical trials in people are small and short. How long the effect lasts is not yet known, and within the scope of our search, the research comparing it with other skin boosters was 1 small study against hyaluronic acid.
• It is managed as human tissue rather than as a drug or medical device, and the MFDS takes the position that cosmetic use is not appropriate. It is also worth knowing that this is a time when its classification and management standards may change.

Precautions and Limits of the Evidence

This article is general information based on papers and reports published up to October 2026, and does not replace individual medical care. Whether the procedure suits you, and what changes you can expect, depend on the condition of your skin.

The comparative clinical trial in people had few participants and a short observation period, and in it the manufacturer supplied the product and one of the authors took part in the product's development as an adviser. Studies that used it as a filler differ in the amount, depth and purpose of use, so they cannot be compared directly. The company's statements on the number of uses and on side effects are not independently confirmed data. The regulatory content is based on reports of statements by the National Assembly and the government, and may change depending on the results of the policy study.

Injection procedures can cause redness, swelling, pain and bruising, and, rarely, infection or nodules and inflammatory reactions.

References

1. Wainwright D, Madden M, Luterman A, et al. Clinical evaluation of an acellular allograft dermal matrix in full-thickness burns. J Burn Care Rehabil. 1996;17(2):124-136.
2. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials. 2011;32(12):3233-3243.
3. Lee YI, Chau NH, Nguyen NH, et al. Injectable particulated human acellular dermal matrix booster for skin restoration: an integrated randomized, split-face, double-blinded clinical trial and preclinical study. Int J Mol Sci. 2026;27(5):2193.
4. Sclafani AP, Romo T 3rd, Jacono AA. Rejuvenation of the aging lip with an injectable acellular dermal graft (Cymetra). Arch Facial Plast Surg. 2002;4(4):252-257.
5. Zhang C, Chang X, et al. Safety and efficacy of micronized acellular dermal matrix injection for correction of moderate to severe nasolabial folds: a double-blind, multicenter, randomized controlled, non-inferior clinical trial. Aesthetic Plast Surg. 2026;50(10):3710-3719.
6. Safety, Management, etc. of Human Tissue Act (Korea). Korea Law Information Center.
7. Dailypharm. Report of April 20, 2026 — remarks by the Ministry of Food and Drug Safety at the National Assembly forum on reasonable regulation for the appropriate use of donated human tissue.
8. MTN, Money Today Broadcasting. Report of April 29, 2026 — briefing by an ECM skin booster manufacturer (its processing method and its position on 'minimal manipulation' and clinical data).
9. Dailypharm. Report of April 30, 2026 — briefing by an ECM skin booster manufacturer (its explanation of the number of uses, lot management and donor consent).
10. Business Plus. Report of October 8, 2026 — questions on ECM skin boosters at the National Assembly's audit of the Ministry of Health and Welfare (October 7).
11. Medical Newspaper. Report of October 13, 2026 — questions on human-tissue skin boosters at the National Assembly's audit of the Ministry of Food and Drug Safety (distribution, adverse reactions, residues, shelf life).
12. Health Kyunghyang. Report of October 13, 2026 — the National Assembly's audit of the Ministry of Food and Drug Safety (classification as human tissue or medical device, advertising wording).
13. MTN, Money Today Broadcasting. Report of October 13, 2026 — the request to refrain from advertising human tissue, and current advertising practices.
14. Dailypharm. Report of October 14, 2026 — the Ministry of Food and Drug Safety's review of its 'minimal manipulation' criteria.

From Consultation Through Treatment

A board-certified dermatologist examines you directly, identifies which layer the cause sits in, sets the device and the parameters, and then carries out the procedure as the same physician. This is not a structure in which a consultant sells the treatment.

The number of sessions, the intervals, the maintenance point and the cost are agreed together before the first session.

Related care: Skin booster information